Sign up to save your podcasts
Or
Share Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.
More shows like Neurology Today in 5
View all
JAMA Editors' Summary
131 Listeners
Global News Podcast
7,677 Listeners
Neurology® Podcast
288 Listeners
NEJM This Week
323 Listeners
Practical Neurology Podcast
46 Listeners
JAMA Clinical Reviews
494 Listeners
JAMA Neurology Author Interviews
14 Listeners
Annals On Call Podcast
186 Listeners
The Clinical Problem Solvers
512 Listeners
Neurology Minute
132 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
351 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
364 Listeners
The Lancet Neurology in conversation with
2 Listeners
Continuum Audio
77 Listeners